TW202115090A - 巨環激酶抑制劑之多晶型 - Google Patents
巨環激酶抑制劑之多晶型 Download PDFInfo
- Publication number
- TW202115090A TW202115090A TW109120778A TW109120778A TW202115090A TW 202115090 A TW202115090 A TW 202115090A TW 109120778 A TW109120778 A TW 109120778A TW 109120778 A TW109120778 A TW 109120778A TW 202115090 A TW202115090 A TW 202115090A
- Authority
- TW
- Taiwan
- Prior art keywords
- cancer
- ret
- polymorphic form
- crystalline
- powder
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962863493P | 2019-06-19 | 2019-06-19 | |
| US62/863,493 | 2019-06-19 | ||
| US202062959940P | 2020-01-11 | 2020-01-11 | |
| US62/959,940 | 2020-01-11 | ||
| US202063036102P | 2020-06-08 | 2020-06-08 | |
| US63/036,102 | 2020-06-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202115090A true TW202115090A (zh) | 2021-04-16 |
Family
ID=74040102
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW109120778A TW202115090A (zh) | 2019-06-19 | 2020-06-19 | 巨環激酶抑制劑之多晶型 |
Country Status (15)
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113336774B (zh) * | 2021-06-25 | 2023-05-23 | 江南大学 | 作为trk抑制剂的取代的手性二芳基大环化合物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015112806A2 (en) * | 2014-01-24 | 2015-07-30 | Tp Therapeutics, Inc. | Diaryl macrocycles as modulators of protein kinases |
| RU2732405C2 (ru) * | 2015-07-02 | 2020-09-16 | Тёрнинг Поинт Терапьютикс, Инк. | Хиральные диарильные макроциклы в качестве модуляторов протеинкиназ |
| BR112018000297A2 (pt) * | 2015-07-06 | 2018-09-04 | Tp Therapeutics Inc | polimorfo de macrociclo de diarila |
| WO2017015367A1 (en) * | 2015-07-21 | 2017-01-26 | Tp Therapeutics, Inc. | Chiral diaryl macrocycles and uses thereof |
| CA3069554A1 (en) * | 2017-07-14 | 2019-01-17 | Glaxosmithkline Intellectual Property Development Limited | Inhibitors of leucine rich repeat kinase 2 |
| RS63787B1 (sr) * | 2017-12-19 | 2022-12-30 | Turning Point Therapeutics Inc | Makrociklična jedinjenja za lečenje bolesti |
-
2020
- 2020-06-16 WO PCT/US2020/037892 patent/WO2020257169A1/en not_active Ceased
- 2020-06-16 MX MX2021015756A patent/MX2021015756A/es unknown
- 2020-06-16 US US17/618,060 patent/US20220411439A1/en not_active Abandoned
- 2020-06-16 JP JP2021575515A patent/JP2022537385A/ja not_active Withdrawn
- 2020-06-16 AU AU2020294627A patent/AU2020294627A1/en not_active Abandoned
- 2020-06-16 PH PH1/2021/553174A patent/PH12021553174A1/en unknown
- 2020-06-16 KR KR1020227001994A patent/KR20220046549A/ko not_active Ceased
- 2020-06-16 EP EP20826665.0A patent/EP3986413A4/en not_active Withdrawn
- 2020-06-16 CA CA3143043A patent/CA3143043A1/en active Pending
- 2020-06-16 BR BR112021025786A patent/BR112021025786A2/pt not_active Application Discontinuation
- 2020-06-16 PE PE2021002184A patent/PE20220135A1/es unknown
- 2020-06-16 CN CN202080044953.1A patent/CN114025765A/zh active Pending
- 2020-06-19 TW TW109120778A patent/TW202115090A/zh unknown
-
2021
- 2021-12-14 IL IL288982A patent/IL288982A/en unknown
-
2022
- 2022-01-19 CO CONC2022/0000405A patent/CO2022000405A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12021553174A1 (en) | 2022-08-01 |
| WO2020257169A1 (en) | 2020-12-24 |
| MX2021015756A (es) | 2022-01-27 |
| AU2020294627A1 (en) | 2022-02-17 |
| IL288982A (en) | 2022-02-01 |
| PE20220135A1 (es) | 2022-01-27 |
| JP2022537385A (ja) | 2022-08-25 |
| BR112021025786A2 (pt) | 2022-02-01 |
| KR20220046549A (ko) | 2022-04-14 |
| CA3143043A1 (en) | 2020-12-24 |
| EP3986413A4 (en) | 2023-06-14 |
| CN114025765A (zh) | 2022-02-08 |
| CO2022000405A2 (es) | 2022-04-29 |
| US20220411439A1 (en) | 2022-12-29 |
| EP3986413A1 (en) | 2022-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7212713B2 (ja) | ジアリール大環状多形 | |
| CN111511746B (zh) | 用于治疗疾病的巨环化合物 | |
| US7173029B2 (en) | Fused heteroaryl derivatives | |
| US20220017520A1 (en) | Macrocyclic compound as cdk inhibitor, preparation method therefor, and use thereof in medicine | |
| CN1608062A (zh) | E-2-甲氧基-n-(3-{4-[3-甲基-4-(6-甲基-吡啶-3-基氧基) -苯氨基]-喹唑啉-6基}-烯丙基)-乙酰胺的盐,其制备和抗癌用途 | |
| JP2019518776A (ja) | Egfr阻害剤としてのアニリンピリミジン化合物の結晶 | |
| IL293458A (en) | Macro rings for use in the treatment of the disease | |
| CN115160309B (zh) | Krasg12c突变蛋白杂环类抑制剂的制备及其应用 | |
| US20220411439A1 (en) | Polymorphs of a macrocyclic kinase inhibitor | |
| CN118652239A (zh) | 一类egfr别构抑制剂的合成及其用途 | |
| JP2006512355A (ja) | E−2−メトキシ−n−(3−{4−[3−メチル−4−(6−メチルピリジン−3−イルオキシ)−フェニルアミノ]−キナゾリン−6−イル}−アリル)−アセトアミドの複合体、それらの製造方法および使用 | |
| WO2022121967A1 (zh) | Egfr酪氨酸激酶抑制剂及其用途 | |
| HK40059224A (en) | Diaryl macrocycle polymorph and method for preparing the same | |
| HK40059224B (en) | Diaryl macrocycle polymorph and method for preparing the same | |
| HK1254492B (en) | Diaryl macrocycle polymorph | |
| HK1071743A (en) | Salt forms of e-2-methoxy-n-(3-(4-(3-methyl-pyridin-3-yloxy)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer |